Revenue Recognition - Performance Obligations - Additional Information (Details) $ in Millions		3 Months Ended	9 Months Ended
	Jul. 27, 2020 obligation	Sep. 30, 2021 USD ($)	Sep. 30, 2021 USD ($) Option
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended			75 days
Number of additional customer options | Option			2
Preclinical MAT2A License | Maximum
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue recognized | $		$ 0.1	$ 0.1
GSK
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended			75 days
GSK Collaboration Agreement
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Number of performance obligations | obligation	6
Pol Theta Program
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended			90 days
WRN Program
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Reimbursement period of costs incurred for quarter ended			75 days
Determination period of costs incurred			75 days